Neurology-focused Biogen and UCB are already rumored to be eyeing an Acorda buyout. But one analyst thinks a host of other major players could join their ranks.
The way Jefferies’ Michael Yee sees it, AbbVie, Allergan, Roche, Shire and Mitsubishi could all get in on the deal action thanks to their neurology infrastructure, Parkinson’s drugs that could complement Acorda candidate Inbrija, or both, he wrote in a Thursday note to clients. He expects Acorda to fetch $2 billion or more in a sale.
Inbrija, which Yee expects will win an FDA OK late this year, “is an attractive asset that could be easily integrated by several neurology companies,” he wrote, adding that he forecasts $300 million to $500 million for the product.
Of course, that’s assuming the FDA accepts Acorda’s application, but the company’s leaders appear “confident that NDA acceptance of the Inbrija package should occur any day now,” Yee wrote.
Activist hedge fund Scopia Capital Management, for one, shares Yee’s view that several biopharma players could end up on Acorda’s list of suitors. Back in August, it wrote to Acorda’s board that “we are highly confident that multiple qualified, potential buyers would be interested in engaging with Acorda,” while piling on the pressure to sell.
Acorda has apparently taken Scopia’s advice to heart. The company, which is scrambling to win an Inbrija thumbs up before knockoffs move in on key multiple sclerosis therapy Ampyra, has tapped Centerview Partners and MTS Health Partners to help it explore a sale, The Wall Street Journal reported last month.
By Carly Helfand
Source: Fierce Pharma
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
